Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone

Bortezomib and dexamethasone with cyclophosphamide (CyBorD) or melphalan (BMDex) are commonly used primary treatments for light-chain (AL) amyloidosis, but limited data exist on bortezomib with immunomodulatory drug combinations. We report our experience with primary therapy with a bortezomib, lenal...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Principais autores: Kastritis, Efstathios, Dialoupi, Ioanna, Gavriatopoulou, Maria, Roussou, Maria, Kanellias, Nikolaos, Fotiou, Despina, Ntanasis-Stathopoulos, Ioannis, Papadopoulou, Elektra, Ziogas, Dimitrios C., Stamatelopoulos, Kimon, Manios, Efstathios, Ntalianis, Argyrios, Eleutherakis-Papaiakovou, Evangelos, Papanikolaou, Asimina, Migkou, Magdalini, Papanota, Aristea-Maria, Gakiopoulou, Harikleia, Psimenou, Erasmia, Tselegkidi, Maria Irini, Tsitsilonis, Ourania, Kostopoulos, Ioannis, Terpos, Evangelos, Dimopoulos, Meletios A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6849948/
https://ncbi.nlm.nih.gov/pubmed/31648323
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000147
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados